CApecitabine plus Radium-223 (Xofigo ™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial

DiscussionThe CARBON study is important as the results will be the first to assess radium-223 with chemotherapy in advanced breast cancer. If the results find acceptable rates of toxicity with a decrease in bone turnover markers, further work will be necessary in a phase II/III setting to assess the efficacy and clinical benefit.Trial registrationISRCTN,ISRCTN92755158, Registered on 17 February 2016.
Source: Trials - Category: Research Source Type: clinical trials

Related Links:

Authors: Rossi G, Zullo L, Cerbone L, Coco S, Longo L, Tagliamento M, Dal Bello MG, Boccardo S, Alama A, Genova C Abstract Introduction: Poly (ADP-ribose) polymerase inhibitors (PARPi) are already part of the armamentarium of drugs available against ovarian and breast cancer. There is less data available on the efficacy of these drugs in the treatment of non-small cell lung cancer (NSCLC).Areas covered: The authors have analyzed the preclinical studies that justified the use of PARPi in NSCLC. They then evaluate the in vivo efficacy of the combination of these drugs with chemotherapy, radiotherapy, and immunotherap...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
ConclusionOur results provide information on the diversity of longitudinal AET adherence patterns, the timing of decline and discontinuation and associated factors that could inform healthcare professionals.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
In this study, we aimed to analyze the relationship between androgen receptor (AR) and EBP1 expression in HER2+ BC. A total of 282 cases (140 cases of HER2+ invasive BC and 142 HER2-negative invasive BC) were included in this study. We performed immunohistochemistry (IHC) to analyze the expression of AR and EBP1; thereafter, we evaluated the relationship between these two biomarkers and estrogen receptor (ER), progesterone receptor (PR), HER2, p53, Ki67 expression, and other clinicopathological parameters. Of the HER2+ cases, 67 (47.9%) showed high expression of EBP1 (EBP1high) and 73 (52.1%) showed low/no expression of EB...
Source: Virchows Archiv - Category: Pathology Source Type: research
Conclusions: Docetaxel and epirubicin neoadjuvant chemotherapy showed a good response in locally advanced breast cancer. Pretreatment Ki-67 and change of Ki-67 may play a role as predictive factor for response to neoadjuvant chemotherapy. PMID: 32069523 [PubMed - as supplied by publisher]
Source: The Korean Journal of Internal Medicine - Category: Internal Medicine Authors: Tags: Korean J Intern Med Source Type: research
Condition:   Early Hormone Receptor-positive Breast Cancer Intervention:   Drug: Chemotherapy Drugs, Cancer Sponsor:   Gencurix, Inc. Recruiting
Source: - Category: Research Source Type: clinical trials
AbstractPurposeTo investigate whether monitoring with ultrasound and MR imaging before, during and after neoadjuvant chemotherapy (NAC) can predict axillary response in breast cancer patients.Materials and methodsA total of 131 breast cancer patients with clinically positive axillary lymph node (LN) who underwent NAC and subsequent surgery were enrolled. They had ultrasound and 3.0 T-MR examinations before, during and after NAC. After reviewing ultrasound and MR images, axillary LN features and tumour size (T size) were noted. According to LN status after surgery, imaging features and their diagnostic performances were ana...
Source: European Radiology - Category: Radiology Source Type: research
This study reports the root causes of recruitment challenges and the strategies used to successfully overcome them.
Source: Clinical Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research
ConclusionsThis survey shows a fairly good use of hRT and a moderate practice of PBI in Italy. Some practices like hRT to the chest wall and regional lymph nodes as well as rRT need further verification. Likewise, the management of post-NAC RT is very heterogeneous. Future national clinical collaborative studies are advocated in order to investigate these controversial topics about breast cancer radiotherapy.
Source: La Radiologia Medica - Category: Radiology Source Type: research
Publication date: Available online 19 February 2020Source: Molecular and Cellular EndocrinologyAuthor(s): Tenghua Yu, Hong Cheng, Zhijuan Ding, Zhiliang Wang, Lixia Zhou, Peng Zhao, Shengxing Tan, Xue Xu, Xianming Huang, Manran Liu, Meixi Peng, Yu-an QiuAbstractRescue chemotherapy is usually the preferred treatment for patients with advanced estrogen receptor-positive (ER+) breast cancer with endocrinotherapy resistance. However, these patients often simultaneously show a poor response to cytotoxic drugs, and thus the detailed mechanism of this resistance needs to be further investigated. Our previous research indicated th...
Source: Molecular and Cellular Endocrinology - Category: Endocrinology Source Type: research
Conclusion EORTC criteria and PERCIST had early predictive value to long-term outcome, but moderate value for pCR. Furthermore, PERCIST might show more potential than the EORTC criteria and conventional PET-based parameters to predict prognosis in breast cancer patients following two cycles of neoadjuvant chemotherapy. Video abstract: see
Source: Nuclear Medicine Communications - Category: Nuclear Medicine Tags: Original Articles Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Research | Study | Toxicology | Xeloda